At Idenix, our primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV. HCV treatment is evolving rapidly with the development of all-oral direct-acting antiviral (DAA) combination therapies that enable increased sustained virologic response (SVR) rates, reduced duration of treatment, and enhanced convenience for patients. Our goal is to discover and develop drug candidates that will play a major role in the emerging treatment paradigm.
Our strategic goal is to develop safe, potent and convenient all-oral DAA combinations that are pan-genotypic without the use of pegylated interferon and ribavirin. Our objective is to develop once-daily agents that have low potential for drug-drug interaction, high tolerability and are designed for use in multiple combination regimens. We are seeking to build a combination development strategy, both internally and with partners, to advance the future of HCV treatments.
Our HCV discovery program is focused on nucleotide polymerase inhibitors and NS5A inhibitors. We believe that nucleotides will have a significant role in a combination DAA strategy for the treatment of HCV and therefore, leveraging our strong nucleotide scientific expertise and our intellectual property portfolio, we are currently concentrating a substantial amount of our discovery efforts on this class of drugs to develop additional novel candidates.